Al MJ - Search Results

1

Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Büyükkaramikli NC, Blommestein HM, Riemsma R, Armstrong N, Clay FJ, Ross J, Worthy G, Severens J, Kleijnen J, Al MJ. Büyükkaramikli NC, et al. Among authors: al mj. Pharmacoeconomics. 2017 Dec;35(12):1211-1221. doi: 10.1007/s40273-017-0528-y. Pharmacoeconomics. 2017. PMID: 28656543 Free PMC article. Review.

2

The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritis.

Al MJ, Michel BC, Rutten FF. Al MJ, et al. Pharmacoeconomics. 1996 Aug;10(2):141-51. doi: 10.2165/00019053-199610020-00006. Pharmacoeconomics. 1996. PMID: 10163417 Clinical Trial.

3

Methods to analyse cost data of patients who withdraw in a clinical trial setting.

Oostenbrink JB, Al MJ, Rutten-van Mölken MP. Oostenbrink JB, et al. Among authors: al mj. Pharmacoeconomics. 2003;21(15):1103-12. doi: 10.2165/00019053-200321150-00004. Pharmacoeconomics. 2003. PMID: 14596629 Clinical Trial.

4

Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in the Netherlands.

Al MJ, Maniadakis N, Grijseels EW, Janssen M. Al MJ, et al. Value Health. 2008 Jul-Aug;11(4):589-99. doi: 10.1111/j.1524-4733.2007.00303.x. Epub 2008 Jan 8. Value Health. 2008. PMID: 18194404 Free article.

5

Expected value of perfect information: an empirical example of reducing decision uncertainty by conducting additional research.

Oostenbrink JB, Al MJ, Oppe M, Rutten-van Mölken MP. Oostenbrink JB, et al. Among authors: al mj. Value Health. 2008 Dec;11(7):1070-80. doi: 10.1111/j.1524-4733.2008.00389.x. Value Health. 2008. PMID: 19602213 Free article.

6

Comparing methods of data synthesis: re-estimating parameters of an existing probabilistic cost-effectiveness model.

Oppe M, Al M, Rutten-van Mölken M. Oppe M, et al. Pharmacoeconomics. 2011 Mar;29(3):239-50. doi: 10.2165/11539870-000000000-00000. Pharmacoeconomics. 2011. PMID: 21142288

7

Developing and applying a stochastic dynamic population model for chronic obstructive pulmonary disease.

Hoogendoorn M, Rutten-van Mölken MP, Hoogenveen RT, Al MJ, Feenstra TL. Hoogendoorn M, et al. Among authors: al mj. Value Health. 2011 Dec;14(8):1039-47. doi: 10.1016/j.jval.2011.06.008. Epub 2011 Sep 22. Value Health. 2011. PMID: 22152172 Free article.

8

Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial.

Hoogendoorn M, Al MJ, Beeh KM, Bowles D, Graf von der Schulenburg JM, Lungershausen J, Monz BU, Schmidt H, Vogelmeier C, Rutten-van Mölken MP. Hoogendoorn M, et al. Among authors: al mj. Eur Respir J. 2013 Mar;41(3):556-64. doi: 10.1183/09031936.00027212. Epub 2012 Jun 14. Eur Respir J. 2013. PMID: 22700844 Free article. Clinical Trial.

9

Cost-effectiveness acceptability curves revisited.

Al MJ. Al MJ. Pharmacoeconomics. 2013 Feb;31(2):93-100. doi: 10.1007/s40273-012-0011-8. Pharmacoeconomics. 2013. PMID: 23329426

10

A systematic review and economic evaluation of new-generation computed tomography scanners for imaging in coronary artery disease and congenital heart disease: Somatom Definition Flash, Aquilion ONE, Brilliance iCT and Discovery CT750 HD.

Westwood M, Al M, Burgers L, Redekop K, Lhachimi S, Armstrong N, Raatz H, Misso K, Severens J, Kleijnen J. Westwood M, et al. Health Technol Assess. 2013;17(9):1-243. doi: 10.3310/hta17090. Health Technol Assess. 2013. PMID: 23463937 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

92 results

Search Page